Aptevo Therapeutics Inc. APVO
Set alert
As of Nov 2, 10:40 AM ET
- YTD
- -85.47%
- 1 year
- -95.09%
- Open
- 1.39
- Prev close
- 1.34
- Mkt cap
- 2.46M
- Vol
- 2.45K
- Avg vol
- 96.57K
- EPS
- 66.96
- P/E
- 0.02
- Div yield
- 0.00%
More statistics
- Low
- 1.35
- High
- 1.39
- Forward P/E
- -0.83
- Beta
- 5.07
- Short ratio
- 0.47
- Inst. own
- 11.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 4, 2024
- 50-d avg
- 8.69
- 200-d avg
- 31.59
- 1y target
- 21.00
News
-
1 week ago benzinga.com
Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing…
2 weeks ago accessnewswire.com
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo…
1 month ago defenseworld.net
Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Rises 59.0%
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling…
-
1 month ago benzinga.com
Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™
1 month ago accessnewswire.com
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in…
1 month ago defenseworld.net
Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report)'s share price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $3.22 and traded…
1 month ago benzinga.com
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia…
1 month ago benzinga.com
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
2 months ago accessnewswire.com
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc.…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by…
-
2 months ago benzinga.com
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
https://patentcenter.uspto.gov/applications/18255342/ifw/docs
-
2 months ago benzinga.com
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of…
2 months ago accessnewswire.com
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive…
-
2 months ago benzinga.com
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously
2 months ago accessnewswire.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific…
2 months ago accessnewswire.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific…
-
3 months ago benzinga.com
Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to…
3 months ago accessnewswire.com
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 /…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
3 months ago benzinga.com
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%, AIBZ +14.3%, BBIO +10%. Losers: AFJK -25.8%, VTAK -19%, APVO -18%, NQ -16.3%.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
-
3 months ago benzinga.com
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".
https://patentcenter.uspto.gov/applications/17634631/ifw/docshttps://x.com/PatentGrants/status/2074946217625493850
4 months ago accessnewswire.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary…
5 months ago accessnewswire.com
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo…
-
5 months ago benzinga.com
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305
-
5 months ago benzinga.com
Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform
5 months ago accessnewswire.com
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI /…
5 months ago zacks.com
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 months ago accessnewswire.com
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed…
-
6 months ago benzinga.com
Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in…
6 months ago accessnewswire.com
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6,…
6 months ago zacks.com
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
7 months ago benzinga.com
Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of…
7 months ago accessnewswire.com
Aptevo Provides State of the Business Report and 2025 Financial Results
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapy…
7 months ago accessnewswire.com
Aptevo to Participate in March 2026 Conferences
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary…
7 months ago defenseworld.net
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
7 months ago benzinga.com
Aptevo Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients; Trials Deliver 86% Clinical Benefit Rate With Zero Patients Experiencing Common Symptom Of CRS
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo…
-
8 months ago benzinga.com
10 Health Care Stocks Moving In Monday's Pre-Market Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
9 months ago benzinga.com
Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies,…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
10 months ago benzinga.com
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 months ago benzinga.com
What's Going On With Aptevo Therapeutics Stock Today?
Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
10 months ago benzinga.com
US Stocks Mixed; Biohaven Shares Fall
US Stocks Mixed; Biohaven Shares Fall
-
10 months ago benzinga.com
Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability…
-
12 months ago benzinga.com
Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of…